Pharma FDI in the times of Covid-19: A challenging pill to swallow

28 April 2020 (Last Updated September 18th, 2020 17:13)

Political and economic stability, and a coherent Covid-19 containment strategy are among the key factors in attracting biopharma FDI. With supply chains disrupted and the world veering all its attention towards halting Covid-19, FDI flows into the pharmaceutical sector will strongly depend on countries’ ability to respond to the epidemic, and their overall stability.

Read more here


In advance of the launch of our FDI-focused site, please complete the following survey aimed at investigating how investment plans are changing in the wake of Covid-19.

Your participation is confidential and the survey will take no longer than 5-10 minutes to complete. As a thank you we will share a copy of the survey write up with you.